Skip to main content
Clinical Trials/ITMCTR2200005671
ITMCTR2200005671
Not yet recruiting
未知

Randomized Controlled Study of Preventive Effect of TDX105 on Regorafenib Induced Dermatologic Toxicities

Cancer hosptial Chinese Academy of Medical Sciences0 sitesTBD
Conditions????

Overview

Phase
未知
Intervention
Not specified
Conditions
????
Sponsor
Cancer hosptial Chinese Academy of Medical Sciences
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Cancer hosptial Chinese Academy of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • 1\. Clinically confirmed colorectal cancer patients;
  • 2\. It is planned to use the targeted drug regorafenib for the first time, and the initial dose is 120mg/d;
  • 3\. PS score \= 3;
  • 4\. Aged \= 18;
  • 5, no intellectual and mental disorders, normal language expression ability, ability to judge their own symptoms
  • 6\. Understand and agree to accept the treatment, and sign the informed consent.

Exclusion Criteria

  • 1\. Patients with skin reactions affected by simultaneous use of other targeted drugs (sorafenib, sunitinib, fruquintinib, etc.), chemotherapy drugs (capecitabine, doxorubicin, etc.) or hand\-foot radiotherapy;
  • 2\. Patients with skin diseases such as eczema, psoriasis and tinea pedis at observed skin sites (namely hands and feet); Patients with skin allergic diseases;
  • 3\. Patients in the study who cannot cooperate with the continuation of this treatment;
  • 4\. Sudden changes in the patient's condition affected and interfered with the researcher.

Outcomes

Primary Outcomes

Not specified

Similar Trials